StockData
Genenta Science S.p.A. logo

Genenta Science S.p.A. (SAEN) stock

SAENNasdaqBiological Products, (No Diagnostic Substances)Also trades as GNTA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.68−0.04 (-5.28%)

Close on Nov 11, 2026Market cap $15.93MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025

Valuation

Market cap
€14.29M
P/E ratio
–
Price to sales
–
Price to book
0.65
Dividend yield
–
Free cash flow yield
-48.13%

Fundamentals

Net income
-€6.53M
EPS, diluted
-0.33 EUR
Free cash flow
-€6.88M

Trading

Previous close
$0.72
Open
$0.70
Day's range
$0.66 – $0.71
Volume
8,487
Average volume (20 days)
152,134
Beta (5 years)
0.26
RSI (14 days)
47.8
Volatility (1 year)
130.9%
Relative volume
0.10×
WACC
7.4%

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.

PeriodSAENS&P 500DifferenceSAEN per yearS&P 500 per year
1 month-13.4%-2.4%−11.0 pts
3 months-47.7%-1.2%−46.5 pts
Year to date-54.4%+12.3%−66.7 pts
1 year-69.1%+12.4%−81.5 pts
3 years-87.4%+78.8%−166.2 pts-49.9%+21.4%

Eight years at a glance

Fiscal years 2018 to 2025, EUR

Operating income

-€6.60M

Net income

-€6.53M

EPS, diluted

-0.33 EUR

Free cash flow

-€6.88M
Reported period

Press releases

Releases Genenta Science S.p.A. filed with the SEC as exhibits to Form 8-K or 6-K

  1. Unveils Saentra Forge as Its New Brand,
    6-K
  2. Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification
    6-K
  3. 6-K exhibit EX-99.1
    6-K
  4. signs Definitive Agreements with Sophia High Tech
    6-K
  5. evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts
    6-K
  6. office: Milan, via Dell’Annunciata 31
    6-K
All press releases and earnings

About Genenta Science S.p.A.

Biological Products, (No Diagnostic Substances)

Genenta Science S.p.A. is a clinical-stage biotechnology company focused on developing cell and gene therapies for the treatment of solid tumors and other cancer indications. The company utilizes cell-based gene therapy platforms, including lentiviral vector-based technologies engineered to target the tumor microenvironment without inducing widespread systemic toxicity. Its clinical development pipeline includes therapeutic candidates designed to harness immune responses against difficult-to-treat malignancies, intended for patients suffering from specialized solid tumor cancers.

Company profile, executives and history

Genenta Science S.p.A. stock: common questions

What is Genenta Science S.p.A.'s stock price?

SAEN closed at $0.68 on Nov 11, 2026, down 5.28% on the day.

What is Genenta Science S.p.A.'s market cap?

Genenta Science S.p.A. was worth $15.93M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.

What is SAEN's P/E ratio?

Genenta Science S.p.A. lost money over fiscal 2025 (diluted EPS -0.33 EUR), so it has no meaningful P/E ratio.

Does Genenta Science S.p.A. pay a dividend?

No. Genenta Science S.p.A. has not paid a cash dividend over the last twelve months.

How has SAEN stock performed over the past year?

Including dividends, SAEN returned -69.1% over the past year, against +12.4% for the S&P 500.

Who are Genenta Science S.p.A.'s competitors?

Companies most similar to Genenta Science S.p.A. by business, industry and size include SLBT, ENGN, CLDI, IPSC, SANA.

See a number that looks wrong?